Updates

IGL/SE/2026-27/73 2nd November, 2026 The Manager (Listing) The Manager (Listing) BSE Limited National Stock Exchange of India Limited 1st Floor, New Trading Ring, Exchange Plaza, C-1, Block G, Rotunda Building, P.J. Towers, Bandra Kurla Complex, Dalal Street, Mumbai – 400 001 Bandra (East), Mumbai- 400 051 Scrip Code: 500201 Symbol: INDIAGLYCO Dear Sirs, Sub.: Material Update in Connection with Ennature Bio Pharma Limited with reference to Observation letter no. NSE/LIST/48932 dated 17th November, 2025 and no. DCS/AMAL/TS/R37/3905/2025-26 dated 19th November, 2025 ("Observation Letters"), issued by the National Stock Exchange of India Limited and BSE Limited (collectively the "Stock Exchanges"), respectively, received in relation to the Scheme of Arrangement. With reference to captioned above, we would like to inform you that Ennature Bio Pharma Limited (“EBL”), through its letter dated 2nd November, 2026, has communicated to the Company certain material events/ updates in relation to EBL, which is enclosed herein as Annexure A. This disclosure is being made in respect of EBL, pursuant to the requirement in the Observation Letters and SEBI Master Circular No. HO/491l 411 4(7)2025-CFD-POD21l 13762/2026 dated 30th January, 2026 (as amended). You are requested to kindly take the same on record. Thanking you, Yours faithfully, For India Glycols Limited Ankur Jain Head (Legal) & Company Secretary Encl: A/a Date: November 02, 2026 India Glycols Limited Plot No. 2-B & 2-C, Sector – 126, Noida, Uttar Pradesh – 201304 Subject: Intimation regarding receipt of Listing and Trading Approvals in connection with the Scheme of Arrangement amongst India Glycols Limited (“Demerged Company”), Ennature Bio Pharma Limited (“Resulting Company 1”) and IGL Spirits Limited (“Resulting Company 2”) and their respective shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 (“Scheme”). Dear Sir/Madam, This is to inform you that Ennature Bio Pharma Limited (“EBPL”) has received the Listing and Trading Approvals from BSE Limited (“BSE”) and National Stock Exchange of India Limited (“NSE”) on November 02, 2026, in respect of the Equity Shares issued and allotted pursuant to the Scheme. The relevant details are as under: • Name of the Stock Exchanges: BSE and NSE • Type of Approval: Listing and Trading Approval • Security Type: Equity Shares • Number of Shares Listed: 2,23,42,255 equity shares of Rs. 5/- each • Date of Approval: November 02, 2026 • Date of Commencement of Trading: November 04, 2026 Copies of the Listing and Trading Approval letters received are available on the websites of BSE and NSE at https://www.bseindia.com/markets/marketinfo/noticescirculars?id=0 and https://www.nseindia.com/resources/exchange-communication-circulars respectively. You are requested to kindly take the above information on record. Thanking You. For Ennature Bio Pharma Limited Preeti Choudhary Company Secretary Ennature Bio Pharma Limited Phone & Fax Email & Website CIN Demerged division of India Glycols Limited +91135-2698620 connect@ennature.com U24290UR2021PLC013005 +91135-2698939 www.ennaturebiopharma.com Registered Office & Head Office Works P.No.4, Pharma City, Selaqui-248197, Dehradun, Uttarakhand, India Plot No. 2,3,4 & 5 Pharma City, Selaqui-248197, Dehradun, Uttarakhand, India 2B, Sector-126, Noida, Gautam Budh Nagar-201304, Uttar Pradesh, India A-1, Industrial Area Bazpur Road, Kashipur, Udham Singh Nagar- 244713, Uttarakhand, India